Validation of the freezing of gait questionnaire in patients with Parkinson's disease
Identifieur interne : 000987 ( Main/Corpus ); précédent : 000986; suivant : 000988Validation of the freezing of gait questionnaire in patients with Parkinson's disease
Auteurs : Nir Giladi ; Joseph Tal ; Tali Azulay ; Oliver Rascol ; David J. Brooks ; Eldad Melamed ; Wolfgang Oertel ; Werner H. Poewe ; Fabrizio Stocchi ; Eduardo TolosaSource :
- Movement Disorders [ 0885-3185 ] ; 2009-04-15.
English descriptors
- KwdEn :
Abstract
To revalidate the Freezing of Gait Questionnaire (FOG‐Q), patients with Parkinson's disease (PD) were randomly assigned to receive rasagiline (1 mg/day) (n = 150), entacapone (200 mg with each dose of levodopa) (n = 150), or placebo (n = 154). Patients were assessed at baseline and after 10 weeks using the FOG‐Q, Unified Parkinson's Disease Rating Scale (UPDRS), Beck Depression Inventory (BDI), and Parkinson's Disease Questionnaire (PDQ‐39). FOG‐Q dimensionality, test–retest reliability, and internal reliability were examined. Convergent and divergent validities were assessed by correlating FOG‐Q with UPDRS, BDI, and PDQ‐39. Comparisons between FOG‐Q item 3 and UPDRS item 14 were also made. Principal component analysis indicated that FOG‐Q measures a single dimension. Test–retest reliability and internal reliability of FOG‐Q score was high. FOG‐Q was best correlated to items of the UPDRS relating to walking, general motor issues, and mobility. Correlations between baseline and endpoint suggested that FOG‐Q item 3 is at least as reliable as UPDRS item 14. At baseline, 85.9% of patients were identified as “Freezers” using FOG‐Q item 3 (≥1) and 44.1% using UPDRS item 14 (≥1) (P < 0.001). FOG‐Q was a reliable tool for the assessment of treatment intervention. FOG‐Q item 3 was effective as a screening question for the presence of FOG. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21745
Links to Exploration step
ISTEX:1E8B00D3E2E11843140BEB664E928F790D6A6A7DLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Validation of the freezing of gait questionnaire in patients with Parkinson's disease</title><author><name sortKey="Giladi, Nir" sort="Giladi, Nir" uniqKey="Giladi N" first="Nir" last="Giladi">Nir Giladi</name><affiliation><mods:affiliation>Movement Disorders Unit, Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel‐Aviv University, Tel‐Aviv, Israel</mods:affiliation></affiliation></author><author><name sortKey="Tal, Joseph" sort="Tal, Joseph" uniqKey="Tal J" first="Joseph" last="Tal">Joseph Tal</name><affiliation><mods:affiliation>TechnoStat Ltd, Hod Hasharon, Israel</mods:affiliation></affiliation></author><author><name sortKey="Azulay, Tali" sort="Azulay, Tali" uniqKey="Azulay T" first="Tali" last="Azulay">Tali Azulay</name><affiliation><mods:affiliation>TechnoStat Ltd, Hod Hasharon, Israel</mods:affiliation></affiliation></author><author><name sortKey="Rascol, Oliver" sort="Rascol, Oliver" uniqKey="Rascol O" first="Oliver" last="Rascol">Oliver Rascol</name><affiliation><mods:affiliation>Service de Pharmacologie Medicale et Clinique, Faculté de Médecine, Toulouse Cedex, France</mods:affiliation></affiliation></author><author><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name><affiliation><mods:affiliation>Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Melamed, Eldad" sort="Melamed, Eldad" uniqKey="Melamed E" first="Eldad" last="Melamed">Eldad Melamed</name><affiliation><mods:affiliation>Department of Neurology, Rabin Medical Centre, Sackler School of Medicine, Tel‐Aviv University, Tel‐Aviv, Israel</mods:affiliation></affiliation></author><author><name sortKey="Oertel, Wolfgang" sort="Oertel, Wolfgang" uniqKey="Oertel W" first="Wolfgang" last="Oertel">Wolfgang Oertel</name><affiliation><mods:affiliation>Centre of Nervous Diseases, Philipps‐University of Marburg, Marburg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Poewe, Werner H" sort="Poewe, Werner H" uniqKey="Poewe W" first="Werner H." last="Poewe">Werner H. Poewe</name><affiliation><mods:affiliation>Department of Neurology, University of Innsbruck, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Stocchi, Fabrizio" sort="Stocchi, Fabrizio" uniqKey="Stocchi F" first="Fabrizio" last="Stocchi">Fabrizio Stocchi</name><affiliation><mods:affiliation>Department of Neuroscience and Neuromed, University La Sapienza, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name><affiliation><mods:affiliation>Neurology Department, Hospital Clinic, Barcelona, Spain</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1E8B00D3E2E11843140BEB664E928F790D6A6A7D</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/mds.21745</idno><idno type="url">https://api.istex.fr/document/1E8B00D3E2E11843140BEB664E928F790D6A6A7D/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000987</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Validation of the freezing of gait questionnaire in patients with Parkinson's disease</title><author><name sortKey="Giladi, Nir" sort="Giladi, Nir" uniqKey="Giladi N" first="Nir" last="Giladi">Nir Giladi</name><affiliation><mods:affiliation>Movement Disorders Unit, Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel‐Aviv University, Tel‐Aviv, Israel</mods:affiliation></affiliation></author><author><name sortKey="Tal, Joseph" sort="Tal, Joseph" uniqKey="Tal J" first="Joseph" last="Tal">Joseph Tal</name><affiliation><mods:affiliation>TechnoStat Ltd, Hod Hasharon, Israel</mods:affiliation></affiliation></author><author><name sortKey="Azulay, Tali" sort="Azulay, Tali" uniqKey="Azulay T" first="Tali" last="Azulay">Tali Azulay</name><affiliation><mods:affiliation>TechnoStat Ltd, Hod Hasharon, Israel</mods:affiliation></affiliation></author><author><name sortKey="Rascol, Oliver" sort="Rascol, Oliver" uniqKey="Rascol O" first="Oliver" last="Rascol">Oliver Rascol</name><affiliation><mods:affiliation>Service de Pharmacologie Medicale et Clinique, Faculté de Médecine, Toulouse Cedex, France</mods:affiliation></affiliation></author><author><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name><affiliation><mods:affiliation>Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Melamed, Eldad" sort="Melamed, Eldad" uniqKey="Melamed E" first="Eldad" last="Melamed">Eldad Melamed</name><affiliation><mods:affiliation>Department of Neurology, Rabin Medical Centre, Sackler School of Medicine, Tel‐Aviv University, Tel‐Aviv, Israel</mods:affiliation></affiliation></author><author><name sortKey="Oertel, Wolfgang" sort="Oertel, Wolfgang" uniqKey="Oertel W" first="Wolfgang" last="Oertel">Wolfgang Oertel</name><affiliation><mods:affiliation>Centre of Nervous Diseases, Philipps‐University of Marburg, Marburg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Poewe, Werner H" sort="Poewe, Werner H" uniqKey="Poewe W" first="Werner H." last="Poewe">Werner H. Poewe</name><affiliation><mods:affiliation>Department of Neurology, University of Innsbruck, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Stocchi, Fabrizio" sort="Stocchi, Fabrizio" uniqKey="Stocchi F" first="Fabrizio" last="Stocchi">Fabrizio Stocchi</name><affiliation><mods:affiliation>Department of Neuroscience and Neuromed, University La Sapienza, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name><affiliation><mods:affiliation>Neurology Department, Hospital Clinic, Barcelona, Spain</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-04-15">2009-04-15</date><biblScope unit="volume">24</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="655">655</biblScope><biblScope unit="page" to="661">661</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">1E8B00D3E2E11843140BEB664E928F790D6A6A7D</idno><idno type="DOI">10.1002/mds.21745</idno><idno type="ArticleID">MDS21745</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>freezing of gait</term><term>rasagiline</term><term>validation</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To revalidate the Freezing of Gait Questionnaire (FOG‐Q), patients with Parkinson's disease (PD) were randomly assigned to receive rasagiline (1 mg/day) (n = 150), entacapone (200 mg with each dose of levodopa) (n = 150), or placebo (n = 154). Patients were assessed at baseline and after 10 weeks using the FOG‐Q, Unified Parkinson's Disease Rating Scale (UPDRS), Beck Depression Inventory (BDI), and Parkinson's Disease Questionnaire (PDQ‐39). FOG‐Q dimensionality, test–retest reliability, and internal reliability were examined. Convergent and divergent validities were assessed by correlating FOG‐Q with UPDRS, BDI, and PDQ‐39. Comparisons between FOG‐Q item 3 and UPDRS item 14 were also made. Principal component analysis indicated that FOG‐Q measures a single dimension. Test–retest reliability and internal reliability of FOG‐Q score was high. FOG‐Q was best correlated to items of the UPDRS relating to walking, general motor issues, and mobility. Correlations between baseline and endpoint suggested that FOG‐Q item 3 is at least as reliable as UPDRS item 14. At baseline, 85.9% of patients were identified as “Freezers” using FOG‐Q item 3 (≥1) and 44.1% using UPDRS item 14 (≥1) (P < 0.001). FOG‐Q was a reliable tool for the assessment of treatment intervention. FOG‐Q item 3 was effective as a screening question for the presence of FOG. © 2007 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Nir Giladi MD</name><affiliations><json:string>Movement Disorders Unit, Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel‐Aviv University, Tel‐Aviv, Israel</json:string></affiliations></json:item><json:item><name>Joseph Tal PhD</name><affiliations><json:string>TechnoStat Ltd, Hod Hasharon, Israel</json:string></affiliations></json:item><json:item><name>Tali Azulay MSc</name><affiliations><json:string>TechnoStat Ltd, Hod Hasharon, Israel</json:string></affiliations></json:item><json:item><name>Oliver Rascol MD, PhD</name><affiliations><json:string>Service de Pharmacologie Medicale et Clinique, Faculté de Médecine, Toulouse Cedex, France</json:string></affiliations></json:item><json:item><name>David J. Brooks MD, DSc</name><affiliations><json:string>Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Eldad Melamed MD</name><affiliations><json:string>Department of Neurology, Rabin Medical Centre, Sackler School of Medicine, Tel‐Aviv University, Tel‐Aviv, Israel</json:string></affiliations></json:item><json:item><name>Wolfgang Oertel MD</name><affiliations><json:string>Centre of Nervous Diseases, Philipps‐University of Marburg, Marburg, Germany</json:string></affiliations></json:item><json:item><name>Werner H. Poewe MD</name><affiliations><json:string>Department of Neurology, University of Innsbruck, Innsbruck, Austria</json:string></affiliations></json:item><json:item><name>Fabrizio Stocchi MD</name><affiliations><json:string>Department of Neuroscience and Neuromed, University La Sapienza, Rome, Italy</json:string></affiliations></json:item><json:item><name>Eduardo Tolosa MD</name><affiliations><json:string>Neurology Department, Hospital Clinic, Barcelona, Spain</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>freezing of gait</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>validation</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>rasagiline</value></json:item></subject><articleId><json:string>MDS21745</json:string></articleId><language><json:string>eng</json:string></language><abstract>To revalidate the Freezing of Gait Questionnaire (FOG‐Q), patients with Parkinson's disease (PD) were randomly assigned to receive rasagiline (1 mg/day) (n = 150), entacapone (200 mg with each dose of levodopa) (n = 150), or placebo (n = 154). Patients were assessed at baseline and after 10 weeks using the FOG‐Q, Unified Parkinson's Disease Rating Scale (UPDRS), Beck Depression Inventory (BDI), and Parkinson's Disease Questionnaire (PDQ‐39). FOG‐Q dimensionality, test–retest reliability, and internal reliability were examined. Convergent and divergent validities were assessed by correlating FOG‐Q with UPDRS, BDI, and PDQ‐39. Comparisons between FOG‐Q item 3 and UPDRS item 14 were also made. Principal component analysis indicated that FOG‐Q measures a single dimension. Test–retest reliability and internal reliability of FOG‐Q score was high. FOG‐Q was best correlated to items of the UPDRS relating to walking, general motor issues, and mobility. Correlations between baseline and endpoint suggested that FOG‐Q item 3 is at least as reliable as UPDRS item 14. At baseline, 85.9% of patients were identified as “Freezers” using FOG‐Q item 3 (≥1) and 44.1% using UPDRS item 14 (≥1) (P > 0.001). FOG‐Q was a reliable tool for the assessment of treatment intervention. FOG‐Q item 3 was effective as a screening question for the presence of FOG. © 2007 Movement Disorder Society</abstract><qualityIndicators><score>6.702</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>4</keywordCount><abstractCharCount>1384</abstractCharCount><pdfWordCount>4158</pdfWordCount><pdfCharCount>25901</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>212</abstractWordCount></qualityIndicators><title>Validation of the freezing of gait questionnaire in patients with Parkinson's disease</title><genre><json:string>article</json:string></genre><host><volume>24</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>7</total><last>661</last><first>655</first></pages><issn><json:string>0885-3185</json:string></issn><issue>5</issue><subject><json:item><value>Research Article</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2009</publicationDate><copyrightDate>2009</copyrightDate><doi><json:string>10.1002/mds.21745</json:string></doi><id>1E8B00D3E2E11843140BEB664E928F790D6A6A7D</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/1E8B00D3E2E11843140BEB664E928F790D6A6A7D/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/1E8B00D3E2E11843140BEB664E928F790D6A6A7D/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/1E8B00D3E2E11843140BEB664E928F790D6A6A7D/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Validation of the freezing of gait questionnaire in patients with Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2009</date></publicationStmt><notesStmt><note>Teva Pharmaceutical Industries Ltd, Research and Development Division, PO Box 8077, Industrial Zone Kiryat Sapir, Netanya, Israel</note><note>H. Lundbeck A/S, Ottiliavej 9, 2500 Valby, Copenhagen, Denmark</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Validation of the freezing of gait questionnaire in patients with Parkinson's disease</title><author><persName><forename type="first">Nir</forename><surname>Giladi</surname></persName><roleName type="degree">MD</roleName><note type="correspondence"><p>Correspondence: Movement Disorders Unit, Tel Aviv Sourasky Medical Center, 6 Weizman Street, Tel‐Aviv 64239, Israel</p></note><affiliation>Movement Disorders Unit, Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel‐Aviv University, Tel‐Aviv, Israel</affiliation></author><author><persName><forename type="first">Joseph</forename><surname>Tal</surname></persName><roleName type="degree">PhD</roleName><affiliation>TechnoStat Ltd, Hod Hasharon, Israel</affiliation></author><author><persName><forename type="first">Tali</forename><surname>Azulay</surname></persName><roleName type="degree">MSc</roleName><affiliation>TechnoStat Ltd, Hod Hasharon, Israel</affiliation></author><author><persName><forename type="first">Oliver</forename><surname>Rascol</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Service de Pharmacologie Medicale et Clinique, Faculté de Médecine, Toulouse Cedex, France</affiliation></author><author><persName><forename type="first">David J.</forename><surname>Brooks</surname></persName><roleName type="degree">MD, DSc</roleName><affiliation>Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom</affiliation></author><author><persName><forename type="first">Eldad</forename><surname>Melamed</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Rabin Medical Centre, Sackler School of Medicine, Tel‐Aviv University, Tel‐Aviv, Israel</affiliation></author><author><persName><forename type="first">Wolfgang</forename><surname>Oertel</surname></persName><roleName type="degree">MD</roleName><affiliation>Centre of Nervous Diseases, Philipps‐University of Marburg, Marburg, Germany</affiliation></author><author><persName><forename type="first">Werner H.</forename><surname>Poewe</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, University of Innsbruck, Innsbruck, Austria</affiliation></author><author><persName><forename type="first">Fabrizio</forename><surname>Stocchi</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neuroscience and Neuromed, University La Sapienza, Rome, Italy</affiliation></author><author><persName><forename type="first">Eduardo</forename><surname>Tolosa</surname></persName><roleName type="degree">MD</roleName><affiliation>Neurology Department, Hospital Clinic, Barcelona, Spain</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-04-15"></date><biblScope unit="volume">24</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="655">655</biblScope><biblScope unit="page" to="661">661</biblScope></imprint></monogr><idno type="istex">1E8B00D3E2E11843140BEB664E928F790D6A6A7D</idno><idno type="DOI">10.1002/mds.21745</idno><idno type="ArticleID">MDS21745</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2009</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>To revalidate the Freezing of Gait Questionnaire (FOG‐Q), patients with Parkinson's disease (PD) were randomly assigned to receive rasagiline (1 mg/day) (n = 150), entacapone (200 mg with each dose of levodopa) (n = 150), or placebo (n = 154). Patients were assessed at baseline and after 10 weeks using the FOG‐Q, Unified Parkinson's Disease Rating Scale (UPDRS), Beck Depression Inventory (BDI), and Parkinson's Disease Questionnaire (PDQ‐39). FOG‐Q dimensionality, test–retest reliability, and internal reliability were examined. Convergent and divergent validities were assessed by correlating FOG‐Q with UPDRS, BDI, and PDQ‐39. Comparisons between FOG‐Q item 3 and UPDRS item 14 were also made. Principal component analysis indicated that FOG‐Q measures a single dimension. Test–retest reliability and internal reliability of FOG‐Q score was high. FOG‐Q was best correlated to items of the UPDRS relating to walking, general motor issues, and mobility. Correlations between baseline and endpoint suggested that FOG‐Q item 3 is at least as reliable as UPDRS item 14. At baseline, 85.9% of patients were identified as “Freezers” using FOG‐Q item 3 (≥1) and 44.1% using UPDRS item 14 (≥1) (P < 0.001). FOG‐Q was a reliable tool for the assessment of treatment intervention. FOG‐Q item 3 was effective as a screening question for the presence of FOG. © 2007 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>freezing of gait</term></item><item><term>validation</term></item><item><term>Parkinson's disease</term></item><item><term>rasagiline</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2007-01-07">Received</change><change when="2007-08-22">Registration</change><change when="2009-04-15">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/1E8B00D3E2E11843140BEB664E928F790D6A6A7D/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="50"><doi origin="wiley" registered="yes">10.1002/mds.v24:5</doi><numberingGroup><numbering type="journalVolume" number="24">24</numbering><numbering type="journalIssue">5</numbering></numberingGroup><coverDate startDate="2009-04-15">15 April 2009</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="30" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.21745</doi><idGroup><id type="unit" value="MDS21745"></id></idGroup><countGroup><count type="pageTotal" number="7"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2009 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2007-01-07"></event><event type="manuscriptRevised" date="2007-07-16"></event><event type="manuscriptAccepted" date="2007-08-22"></event><event type="publishedOnlineEarlyUnpaginated" date="2009-01-06"></event><event type="firstOnline" date="2009-01-06"></event><event type="publishedOnlineFinalForm" date="2009-04-24"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">655</numbering><numbering type="pageLast">661</numbering></numberingGroup><correspondenceTo>Movement Disorders Unit, Tel Aviv Sourasky Medical Center, 6 Weizman Street, Tel‐Aviv 64239, Israel</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS21745.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="4"></count><count type="referenceTotal" number="24"></count><count type="wordTotal" number="5021"></count></countGroup><titleGroup><title type="main" xml:lang="en">Validation of the freezing of gait questionnaire in patients with Parkinson's disease</title><title type="short" xml:lang="en">Validation of FOG Questionnaire</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Nir</givenNames><familyName>Giladi</familyName><degrees>MD</degrees></personName><contactDetails><email>nirg@tasmc.health.gov.il</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Joseph</givenNames><familyName>Tal</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Tali</givenNames><familyName>Azulay</familyName><degrees>MSc</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Oliver</givenNames><familyName>Rascol</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af4"><personName><givenNames>David J.</givenNames><familyName>Brooks</familyName><degrees>MD, DSc</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Eldad</givenNames><familyName>Melamed</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Wolfgang</givenNames><familyName>Oertel</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af7"><personName><givenNames>Werner H.</givenNames><familyName>Poewe</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af8"><personName><givenNames>Fabrizio</givenNames><familyName>Stocchi</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au10" creatorRole="author" affiliationRef="#af9"><personName><givenNames>Eduardo</givenNames><familyName>Tolosa</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="IL" type="organization"><unparsedAffiliation>Movement Disorders Unit, Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel‐Aviv University, Tel‐Aviv, Israel</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="IL" type="organization"><unparsedAffiliation>TechnoStat Ltd, Hod Hasharon, Israel</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="FR" type="organization"><unparsedAffiliation>Service de Pharmacologie Medicale et Clinique, Faculté de Médecine, Toulouse Cedex, France</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="GB" type="organization"><unparsedAffiliation>Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="IL" type="organization"><unparsedAffiliation>Department of Neurology, Rabin Medical Centre, Sackler School of Medicine, Tel‐Aviv University, Tel‐Aviv, Israel</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="DE" type="organization"><unparsedAffiliation>Centre of Nervous Diseases, Philipps‐University of Marburg, Marburg, Germany</unparsedAffiliation></affiliation><affiliation xml:id="af7" countryCode="AT" type="organization"><unparsedAffiliation>Department of Neurology, University of Innsbruck, Innsbruck, Austria</unparsedAffiliation></affiliation><affiliation xml:id="af8" countryCode="IT" type="organization"><unparsedAffiliation>Department of Neuroscience and Neuromed, University La Sapienza, Rome, Italy</unparsedAffiliation></affiliation><affiliation xml:id="af9" countryCode="ES" type="organization"><unparsedAffiliation>Neurology Department, Hospital Clinic, Barcelona, Spain</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">freezing of gait</keyword><keyword xml:id="kwd2">validation</keyword><keyword xml:id="kwd3">Parkinson's disease</keyword><keyword xml:id="kwd4">rasagiline</keyword></keywordGroup><fundingInfo><fundingAgency>Teva Pharmaceutical Industries Ltd, Research and Development Division, PO Box 8077, Industrial Zone Kiryat Sapir, Netanya, Israel</fundingAgency></fundingInfo><fundingInfo><fundingAgency>H. Lundbeck A/S, Ottiliavej 9, 2500 Valby, Copenhagen, Denmark</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>To revalidate the Freezing of Gait Questionnaire (FOG‐Q), patients with Parkinson's disease (PD) were randomly assigned to receive rasagiline (1 mg/day) (n = 150), entacapone (200 mg with each dose of levodopa) (n = 150), or placebo (n = 154). Patients were assessed at baseline and after 10 weeks using the FOG‐Q, Unified Parkinson's Disease Rating Scale (UPDRS), Beck Depression Inventory (BDI), and Parkinson's Disease Questionnaire (PDQ‐39). FOG‐Q dimensionality, test–retest reliability, and internal reliability were examined. Convergent and divergent validities were assessed by correlating FOG‐Q with UPDRS, BDI, and PDQ‐39. Comparisons between FOG‐Q item 3 and UPDRS item 14 were also made. Principal component analysis indicated that FOG‐Q measures a single dimension. Test–retest reliability and internal reliability of FOG‐Q score was high. FOG‐Q was best correlated to items of the UPDRS relating to walking, general motor issues, and mobility. Correlations between baseline and endpoint suggested that FOG‐Q item 3 is at least as reliable as UPDRS item 14. At baseline, 85.9% of patients were identified as “Freezers” using FOG‐Q item 3 (≥1) and 44.1% using UPDRS item 14 (≥1) (<i>P</i> < 0.001). FOG‐Q was a reliable tool for the assessment of treatment intervention. FOG‐Q item 3 was effective as a screening question for the presence of FOG. © 2007 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Validation of the freezing of gait questionnaire in patients with Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Validation of FOG Questionnaire</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Validation of the freezing of gait questionnaire in patients with Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">Nir</namePart><namePart type="family">Giladi</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Movement Disorders Unit, Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel‐Aviv University, Tel‐Aviv, Israel</affiliation><description>Correspondence: Movement Disorders Unit, Tel Aviv Sourasky Medical Center, 6 Weizman Street, Tel‐Aviv 64239, Israel</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Joseph</namePart><namePart type="family">Tal</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>TechnoStat Ltd, Hod Hasharon, Israel</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Tali</namePart><namePart type="family">Azulay</namePart><namePart type="termsOfAddress">MSc</namePart><affiliation>TechnoStat Ltd, Hod Hasharon, Israel</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Oliver</namePart><namePart type="family">Rascol</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Service de Pharmacologie Medicale et Clinique, Faculté de Médecine, Toulouse Cedex, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">David J.</namePart><namePart type="family">Brooks</namePart><namePart type="termsOfAddress">MD, DSc</namePart><affiliation>Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Eldad</namePart><namePart type="family">Melamed</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Rabin Medical Centre, Sackler School of Medicine, Tel‐Aviv University, Tel‐Aviv, Israel</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Wolfgang</namePart><namePart type="family">Oertel</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Centre of Nervous Diseases, Philipps‐University of Marburg, Marburg, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Werner H.</namePart><namePart type="family">Poewe</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Innsbruck, Innsbruck, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Fabrizio</namePart><namePart type="family">Stocchi</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neuroscience and Neuromed, University La Sapienza, Rome, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Eduardo</namePart><namePart type="family">Tolosa</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Neurology Department, Hospital Clinic, Barcelona, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2009-04-15</dateIssued><dateCaptured encoding="w3cdtf">2007-01-07</dateCaptured><dateValid encoding="w3cdtf">2007-08-22</dateValid><copyrightDate encoding="w3cdtf">2009</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">4</extent><extent unit="references">24</extent><extent unit="words">5021</extent></physicalDescription><abstract lang="en">To revalidate the Freezing of Gait Questionnaire (FOG‐Q), patients with Parkinson's disease (PD) were randomly assigned to receive rasagiline (1 mg/day) (n = 150), entacapone (200 mg with each dose of levodopa) (n = 150), or placebo (n = 154). Patients were assessed at baseline and after 10 weeks using the FOG‐Q, Unified Parkinson's Disease Rating Scale (UPDRS), Beck Depression Inventory (BDI), and Parkinson's Disease Questionnaire (PDQ‐39). FOG‐Q dimensionality, test–retest reliability, and internal reliability were examined. Convergent and divergent validities were assessed by correlating FOG‐Q with UPDRS, BDI, and PDQ‐39. Comparisons between FOG‐Q item 3 and UPDRS item 14 were also made. Principal component analysis indicated that FOG‐Q measures a single dimension. Test–retest reliability and internal reliability of FOG‐Q score was high. FOG‐Q was best correlated to items of the UPDRS relating to walking, general motor issues, and mobility. Correlations between baseline and endpoint suggested that FOG‐Q item 3 is at least as reliable as UPDRS item 14. At baseline, 85.9% of patients were identified as “Freezers” using FOG‐Q item 3 (≥1) and 44.1% using UPDRS item 14 (≥1) (P < 0.001). FOG‐Q was a reliable tool for the assessment of treatment intervention. FOG‐Q item 3 was effective as a screening question for the presence of FOG. © 2007 Movement Disorder Society</abstract><note type="funding">Teva Pharmaceutical Industries Ltd, Research and Development Division, PO Box 8077, Industrial Zone Kiryat Sapir, Netanya, Israel</note><note type="funding">H. Lundbeck A/S, Ottiliavej 9, 2500 Valby, Copenhagen, Denmark</note><subject lang="en"><genre>Keywords</genre><topic>freezing of gait</topic><topic>validation</topic><topic>Parkinson's disease</topic><topic>rasagiline</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><detail type="issue"><caption>no.</caption><number>5</number></detail><extent unit="pages"><start>655</start><end>661</end><total>7</total></extent></part></relatedItem><identifier type="istex">1E8B00D3E2E11843140BEB664E928F790D6A6A7D</identifier><identifier type="DOI">10.1002/mds.21745</identifier><identifier type="ArticleID">MDS21745</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2009 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000987 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000987 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:1E8B00D3E2E11843140BEB664E928F790D6A6A7D
|texte= Validation of the freezing of gait questionnaire in patients with Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |